V
Vladimir Yutkin
Researcher at Hebrew University of Jerusalem
Publications - 56
Citations - 2268
Vladimir Yutkin is an academic researcher from Hebrew University of Jerusalem. The author has contributed to research in topics: Bladder cancer & Medicine. The author has an hindex of 14, co-authored 48 publications receiving 1906 citations.
Papers
More filters
Journal ArticleDOI
Decidual NK cells regulate key developmental processes at the human fetal-maternal interface
Jacob H. Hanna,Debra Goldman-Wohl,Yaron Hamani,Inbal Avraham,Caryn Greenfield,Shira Natanson-Yaron,Diana Prus,Leonor Cohen-Daniel,Tal I. Arnon,Irit Manaster,Roi Gazit,Vladimir Yutkin,Daniel Benharroch,Angel Porgador,Eli Keshet,Simcha Yagel,Ofer Mandelboim +16 more
TL;DR: It is shown that dNK cells, but not peripheral blood–derived NK subsets, regulate trophoblast invasion both in vitro and in vivo by production of the interleukin-8 and interferon-inducible protein–10 chemokines.
Journal ArticleDOI
DNA Based Therapy with Diphtheria Toxin-A BC-819: A Phase 2b Marker Lesion Trial in Patients with Intermediate Risk Nonmuscle Invasive Bladder Cancer
Ofer N. Gofrit,Shalva Benjamin,Sarel Halachmi,Ilan Leibovitch,Zohar A. Dotan,Donald L. Lamm,Nahum Ehrlich,Vladimir Yutkin,Monique Ben-Am,Abraham Hochberg +9 more
TL;DR: BC-819 prevented new tumor growth in two-thirds of the patients and ablated a third of the marker lesions make BC- 819 a potential medication for bladder cancer.
Journal ArticleDOI
Extracorporeal Shock Wave Lithotripsy in Prepubertal Children: 22-Year Experience at a Single Institution With a Single Lithotriptor
Ezekiel H. Landau,Ofer Z. Shenfeld,Dov Pode,Amos Shapiro,Shimon Meretyk,Giora Katz,Ran Katz,Mordechai Duvdevani,Benjamin Hardak,Helio Cipele,Guy Hidas,Vladimir Yutkin,Ofer N. Gofrit +12 more
TL;DR: The 3-month stone-free rate after ESWL in prepubertal patients is 80% and 20% of patients require additional procedures, and ESWWL has inferior results for cystine stones compared to other calculi.
Journal ArticleDOI
Is radical cystectomy mandatory in every patient with variant histology of bladder cancer.
Nandakishore Shapur,Ran Katz,Dov Pode,Amos Shapiro,Vladimir Yutkin,Galina Pizov,Liat Appelbaum,Kevin C. Zorn,Mordechai Duvdevani,Ezekiel H. Landau,Ofer N. Gofrit +10 more
TL;DR: Although progression to muscle invasive disease is more common than in conventional group and occurs in about 40% of the patients, life expectancy is similar to patients with conventional high-grade urothelial carcinomas provided that follow-up is meticulous.
Journal ArticleDOI
β-TrCP Inhibition Reduces Prostate Cancer Cell Growth via Upregulation of the Aryl Hydrocarbon Receptor
TL;DR: It is maintained that combining β-TrCP inhibition with androgen ablation could benefit advanced prostate cancer patients and that AhR activation may be a cancer counteracting mechanism in the prostate.